Search
Neurogene Inc
NGNEAdd to Watchlist
31.530USD
+0.740+2.40%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
498.23MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Neurogene Inc is 8.89, ranking 40 out of 389 in the Biotechnology & Medical Research industry. The average price target is 60.00, with a high of 70.00 and a low of 46.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
80.000
Target Price
+153.73%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Neurogene Inc
NGNE
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Neurogene Inc's price target?
Analysts forecast that Neurogene Inc's price target is USD 60.00, with the highest forecast at USD 70.00 and the lowest forecast at USD 46.00.
How have Neurogene IncNGNE's recent earnings per share performed?
The market expectation was USD -1.39, while Neurogene IncNGNE's earnings per share (EPS) for the previous quarter was USD -1.12. EPS for the next quarter is expected at USD -1.43.
What is the analyst rating for Neurogene Inc?
Based on the ratings of Neurogene Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
